LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 26

Suchoptionen

Artikel: Identification of Shared Neoantigens in

Ruangapirom, Lucksica / Sutivijit, Nannapat / Teerapakpinyo, Chinachote / Mutirangura, Apiwat / Doungkamchan, Chatchanan

Vaccines

2022 Band 10, Heft 10

Abstract: Personalized neoantigen-based cancer vaccines have been shown to be safe and immunogenic in cancer patients; however, the manufacturing process can be costly and bring about delays in treatment. Using off-the-shelf cancer vaccines targeting shared ... ...

Abstract	Personalized neoantigen-based cancer vaccines have been shown to be safe and immunogenic in cancer patients; however, the manufacturing process can be costly and bring about delays in treatment. Using off-the-shelf cancer vaccines targeting shared neoantigens may circumvent these problems. Unique mutational signatures and similar phenotypes found among
Sprache	Englisch
Erscheinungsdatum	2022-09-22
Erscheinungsland	Switzerland
Dokumenttyp	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines10101597
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Correction: The association between vitamin D receptor polymorphism and phases of chronic hepatitis B infection in HBV carriers in Thailand.

Ananchuensook, Prooksa / Suksawatamnauy, Sirinporn / Thaimai, Panarat / Sriphoosanaphan, Supachaya / Thanapirom, Kessarin / Teerapakpinyo, Chinachote / Poovorawan, Yong / Komolmit, Piyawat

PloS one

2024 Band 19, Heft 5, Seite(n) e0303545

Abstract: This corrects the article DOI: 10.1371/journal.pone.0277907.]. ...

Abstract	[This corrects the article DOI: 10.1371/journal.pone.0277907.].
Sprache	Englisch
Erscheinungsdatum	2024-05-07
Erscheinungsland	United States
Dokumenttyp	Published Erratum
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0303545
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Tubulovillous Adenoma of Vagina With Both KRAS and APC Mutations: Case Report.

Shuangshoti, Somruetai / Teerapakpinyo, Chinachote

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

2018 Band 38, Heft 5, Seite(n) 498–501

Abstract: Adenomatous polyps of the vulva and vagina are extremely rare. We report a case of a 74-yr-old women with a tubulovillous adenoma occurring in the vagina, and a second one occurring later in the vulva. Tumor cells in both lesions were CK7, CK20, CDX-2, ... ...

Abstract	Adenomatous polyps of the vulva and vagina are extremely rare. We report a case of a 74-yr-old women with a tubulovillous adenoma occurring in the vagina, and a second one occurring later in the vulva. Tumor cells in both lesions were CK7, CK20, CDX-2, and showed intact mismatch-repair proteins. A G13D (c.38G>A, p.Gly13Asp) mutation in the KRAS gene was identified in both masses. As well, a novel frameshift truncating mutation (c.4320delA, p.Pro1441fsTer32) in the APC gene was detected only in the vaginal mass, ruling out the possibility that the vulvar mass was a local recurrence of the vaginal mass. This is the first identification of KRAS and APC gene mutations in adenomatous polyps involving the female lower genital tract.
Mesh-Begriff(e)	Adenoma/genetics ; Aged ; Female ; Genes, APC ; Humans ; Mutation ; Proto-Oncogene Proteins p21(ras)/genetics ; Vaginal Neoplasms/genetics ; Vulvar Neoplasms/genetics
Chemische Substanzen	KRAS protein, human ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Sprache	Englisch
Erscheinungsdatum	2018-11-28
Erscheinungsland	United States
Dokumenttyp	Case Reports ; Journal Article
ZDB-ID	604859-6
ISSN	1538-7151 ; 0277-1691
ISSN (online)	1538-7151
ISSN	0277-1691
DOI	10.1097/PGP.0000000000000561
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1814: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.

Akkhasutthikun, Patinya / Kaewsapsak, Pornchai / Nimsamer, Pattaraporn / Klomkliew, Pavit / Visedthorn, Suthida / Chanchaem, Pragwalai / Teerapakpinyo, Chinachote / Payungporn, Sunchai / Luangdilok, Sutima

Cancer research and treatment

2023 Band 56, Heft 2, Seite(n) 455–463

Abstract: Purpose: The epidermal growth factor receptor (EGFR) mutation is a widely prevalent oncogene driver in non-small cell lung cancer (NSCLC) in East Asia. The detection of EGFR mutations is a standard biomarker test performed routinely in patients with ... ...

Abstract	Purpose: The epidermal growth factor receptor (EGFR) mutation is a widely prevalent oncogene driver in non-small cell lung cancer (NSCLC) in East Asia. The detection of EGFR mutations is a standard biomarker test performed routinely in patients with NSCLC for the selection of targeted therapy. Here, our objective was to develop a portable new technique for detecting EGFR (19Del, T790M, and L858R) mutations based on Nanopore sequencing. Materials and methods: The assay employed a blocker displacement amplification (BDA)-based polymerase chain reaction (PCR) technique combined with Nanopore sequencing to detect EGFR mutations. Mutant and wild-type EGFR clones were generated from DNA from H1650 (19Del heterozygous) and H1975 (T790M and L858R heterozygous) lung cancer cell lines. Then, they were mixed to assess the performance of this technique for detecting low variant allele frequencies (VAFs). Subsequently, formalin-fixed, paraffin-embedded (FFPE) tissue and cell-free DNA (cfDNA) from patients with NSCLC were used for clinical validation. Results: The assay can detect low VAF at 0.5% mutant mixed in wild-type EGFR. Using FFPE DNA, the concordance rates of EGFR 19Del, T790M, and L858R mutations between our method and Cobas real-time PCR were 98.46%, 100%, and 100%, respectively. For cfDNA, the concordance rates of EGFR 19Del, T790M, and L858R mutations between our method and droplet digital PCR were 94.74%, 100%, and 100%, respectively. Conclusion: The BDA amplicon Nanopore sequencing is a highly accurate and sensitive method for the detection of EGFR mutations in clinical specimens.
Mesh-Begriff(e)	Humans ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/genetics ; Cell-Free Nucleic Acids/genetics ; DNA, Neoplasm ; ErbB Receptors/genetics ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Mutation ; Nanopore Sequencing/methods ; Protein Kinase Inhibitors/therapeutic use ; Real-Time Polymerase Chain Reaction
Chemische Substanzen	Cell-Free Nucleic Acids ; DNA, Neoplasm ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors
Sprache	Englisch
Erscheinungsdatum	2023-11-20
Erscheinungsland	Korea (South)
Dokumenttyp	Journal Article
ZDB-ID	2133613-1
ISSN	2005-9256 ; 1598-2998
ISSN (online)	2005-9256
ISSN	1598-2998
DOI	10.4143/crt.2023.1108
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 7043: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.

Dankai, Wiyada / Pongsuvareeyakul, Tip / Phinyo, Phichayut / Tejamai, Chontichaporn / Teerapakpinyo, Chinachote / Cheewakriangkrai, Chalong / Lekawanvijit, Suree / Siriaunkgul, Sumalee / Khunamornpong, Surapan

BMC women's health

2023 Band 23, Heft 1, Seite(n) 605

Abstract: Background: Endometrial carcinoma is molecularly categorized into four subgroups: polymerase-E exonuclease domain-mutant (POLE-mut), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), and no specific molecular profile (NSMP). This classification ...

Abstract	Background: Endometrial carcinoma is molecularly categorized into four subgroups: polymerase-E exonuclease domain-mutant (POLE-mut), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), and no specific molecular profile (NSMP). This classification scheme has been included into clinical recommendation for post-operative risk-based management, although there have been few Asian studies on this topic. The present study aimed to evaluate the prevalence and clinical outcomes of endometrial carcinoma using this classification in Northern Thailand and the feasibility of implementation in resource-limited settings. Methods: Endometrial carcinomas from hysterectomy specimens were classified using immunohistochemistry for MMR proteins and p53, as well as POLE mutation testing. Clinicopathological variables and outcomes were analyzed. The costs of the molecular information-based approach were compared to those incurred by the conventional approach (without molecular classification). Results: Of 138 patients, 52.9% in the NSMP subgroup, 28.2% were in the MMR-d, 13.8% in the p53-abn, and 5.1% in the POLE-mut. After adjusting for other variables, patients with POLE-mut showed the most favorable outcomes, while those with p53-abn had the poorest survival. When estimating the costs for post-operative management, the use of molecular classification resulted in a 10% increase over the conventional approach. However, the cost increased only by 1% if only POLE testing was used to identify patients for treatment omission. Conclusion: In Northern Thailand, endometrial carcinoma had comparable subgroup distribution and prognostic implications to previous reports, supporting the implementation of management guidelines that incorporate molecular information. In resource-limited settings, at least POLE mutation testing in early-stage patients should be considered.
Mesh-Begriff(e)	Female ; Humans ; Tumor Suppressor Protein p53/genetics ; Resource-Limited Settings ; Thailand ; Endometrial Neoplasms/pathology ; Prognosis ; Mutation ; Biomarkers, Tumor
Chemische Substanzen	Tumor Suppressor Protein p53 ; Biomarkers, Tumor
Sprache	Englisch
Erscheinungsdatum	2023-11-14
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2050444-5
ISSN	1472-6874 ; 1472-6874
ISSN (online)	1472-6874
ISSN	1472-6874
DOI	10.1186/s12905-023-02677-6
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report.

Boongird, Atthaporn / Lekcharoensombat, Nopphon / Jinawath, Artit / Theparee, Talent / Jittapiromsak, Nutchawan / Shuangshoti, Shanop / Thorner, Paul Scott / Teerapakpinyo, Chinachote

Genes, chromosomes & cancer

2023 Band 62, Heft 7, Seite(n) 423–429

Abstract: Glioblastoma (GBM) is a high-grade adult-type IDH-wildtype diffuse glioma, commonly harboring epidermal growth factor receptor (EGFR) amplification. Here, we describe a case of a 49-year-old man with a GBM harboring a TERT promoter mutation. Despite ... ...

Abstract	Glioblastoma (GBM) is a high-grade adult-type IDH-wildtype diffuse glioma, commonly harboring epidermal growth factor receptor (EGFR) amplification. Here, we describe a case of a 49-year-old man with a GBM harboring a TERT promoter mutation. Despite surgical and chemoradiation therapy, the tumor recurred. At that time, comprehensive genomic profiling by next-generation sequencing identified two rare mutations in EGFR: T790M and an exon 20 insertion. Based on these findings, the patient elected to undergo off-label therapy with osimertinib, a third-generation EGFR tyrosine kinase inhibitor that has shown promising results in non-small cell lung carcinoma, including metastatic to brain, with exactly the same EGFR mutations. Moreover, the drug has excellent central nervous system penetration. Even so, no clinical response was observed, and the patient succumbed to the disease. The lack of response may be related to the specific nature of the EGFR mutations, and/or other unfavorable tumor biology overriding any benefit from osimertinib.
Mesh-Begriff(e)	Male ; Adult ; Humans ; Middle Aged ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Glioblastoma/drug therapy ; Glioblastoma/genetics ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Neoplasm Recurrence, Local ; Glioma
Chemische Substanzen	osimertinib (3C06JJ0Z2O) ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1)
Sprache	Englisch
Erscheinungsdatum	2023-04-10
Erscheinungsland	United States
Dokumenttyp	Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1018988-9
ISSN	1098-2264 ; 1045-2257
ISSN (online)	1098-2264
ISSN	1045-2257
DOI	10.1002/gcc.23143
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2966: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel: Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer.

Manchana, Tarinee / Phowthongkum, Prasit / Teerapakpinyo, Chinachote

World journal of clinical oncology

2019 Band 10, Heft 11, Seite(n) 358–368

Abstract: Background: Genetic testing is widely recommended for all epithelial ovarian cancer (EOC) patients. However, an increased probability of identifying germline mutations has been reported in selected patients with risk factors such as a family history or ... ...

Abstract	Background: Genetic testing is widely recommended for all epithelial ovarian cancer (EOC) patients. However, an increased probability of identifying germline mutations has been reported in selected patients with risk factors such as a family history or personal history of cancer and high-grade serous carcinoma (HGSC) subtype. HGSC has been reported to be the most common subtype of EOC worldwide (approximately 70%). However, this subtype is less prevalent in Thai patients (reported as only 20%). The difference in the distribution of various subtypes of EOC may reflect the incidence of germline mutations in Thai EOC patients. Aim: To evaluate the frequencies of germline mutations in EOC patients and to compare the frequencies in those with and without clinical risk factors for hereditary ovarian cancer. Methods: This cross-sectional study included 112 nonmucinous EOC patients who underwent primary surgery at our tertiary care hospital. Clinical risk factors for hereditary ovarian cancer were defined as follows: Age below 40 years, a significant family history of cancer, synchronous ovarian and endometrial cancer, and HGSC. Comprehensive germline mutations were detected by next-generation sequencing. Results: Of a total of 112 patients, 82 (73.2%) patients had ≥ 1 risk factor and 30 (26.8%) patients had no risk factors. Germline mutations were detected in 26 patients: 20 (17.8%) patients had Conclusion: Approximately one-third of EOC patients with risk factors had germline mutations. Almost all germline
Sprache	Englisch
Erscheinungsdatum	2019-04-24
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2587357-X
ISSN	2218-4333
ISSN	2218-4333
DOI	10.5306/wjco.v10.i11.358
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction.

Zungsontiporn, Nicha / Ouwongprayoon, Pongsakorn / Boonsirikamchai, Piyaporn / Leelayuwatanakul, Nophol / Vinayanuwattikun, Chanida / Moonai, Kantika / Khongkhaduead, Ekkachai / Thorner, Paul Scott / Shuangshoti, Shanop / Teerapakpinyo, Chinachote

Pathology, research and practice

2024 Band 255, Seite(n) 155213

Abstract: Background: Digital platforms for mutation detection yield higher sensitivity than non-digital platforms but lack universal positive cut-off values that correlate with the outcome of osimertinib treatment. This study determined compared droplet digital ... ...

Abstract	Background: Digital platforms for mutation detection yield higher sensitivity than non-digital platforms but lack universal positive cut-off values that correlate with the outcome of osimertinib treatment. This study determined compared droplet digital polymerase chain reaction (ddPCR) to the standard cobas assay for epithelial growth factor receptor (EGFR) T790M mutation detection in patients with non-small cell lung cancer. Methods: Study patients had EGFR-mutant tumours with disease progression on first/second generation EGFR tyrosine kinase inhibitors, and osimertinib treatment after T790M mutation detection. T790M status was tested by cobas assay using liquid biopsy, and only by ddPCR if an EGFR mutation was identified but T790M was negative. Clinical efficacy of osimertinib was compared between patients with T790M detected by cobas vs. only by ddPCR. A positive cut-off value for ddPCR was determined by assessing efficacy with osimertinib. Results: 61 patients had tumors with an acquired T790M mutation, 38 detected by cobas and an additional 23 only by ddPCR. The median progression-free survival (PFS) for the cobas- and ddPCR-positive groups was 9.5 and 7.8 months, respectively (p=0.43). For ddPCR, a fractional abundance (FA) of 0.1% was used as a cut-off value. The median PFS of patients with FA ≥0.1% and <0.1% was 8.3 and 4.6 months, respectively (p=0.08). FA ≥0.1% was independently associated with a longer PFS. Conclusion: Using ddPCR to follow up the cobas assay yielded more cases (38% of total) with a T790M mutation. A cut-off value of FA ≥0.1% identified patients who responded as well to osimertinib as those identified by cobas assay. This sequential approach should detect additional patients who might benefit from osimertinib treatment.
Mesh-Begriff(e)	Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; ErbB Receptors ; Real-Time Polymerase Chain Reaction ; Protein Kinase Inhibitors/therapeutic use ; Mutation/genetics ; Liquid Biopsy ; Acrylamides ; Aniline Compounds ; Indoles ; Pyrimidines
Chemische Substanzen	osimertinib (3C06JJ0Z2O) ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1) ; Acrylamides ; Aniline Compounds ; Indoles ; Pyrimidines
Sprache	Englisch
Erscheinungsdatum	2024-02-16
Erscheinungsland	Germany
Dokumenttyp	Journal Article
ZDB-ID	391889-0
ISSN	1618-0631 ; 0344-0338
ISSN (online)	1618-0631
ISSN	0344-0338
DOI	10.1016/j.prp.2024.155213
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ud III Zs.20: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: MicroRNA Expression Profiling in Hydatidiform Mole for the Prediction of Postmolar GTN : MicroRNA Profile in Postmolar GTN.

Teerapakpinyo, Chinachote / Areeruk, Wilasinee / Tantbirojn, Patou / Phupong, Vorapong / Shuangshoti, Shanop / Lertkhachonsuk, Ruangsak

Technology in cancer research & treatment

2021 Band 21, Seite(n) 15330338211067309

Abstract: Objectives: ...

Abstract	Objectives:
Mesh-Begriff(e)	Adolescent ; Adult ; Biomarkers ; Case-Control Studies ; Computational Biology/methods ; Disease Susceptibility ; Female ; Gene Expression Profiling ; Gene Expression Regulation ; Gestational Trophoblastic Disease/diagnosis ; Gestational Trophoblastic Disease/etiology ; Gestational Trophoblastic Disease/metabolism ; Humans ; Hydatidiform Mole/genetics ; Hydatidiform Mole/metabolism ; Hydatidiform Mole/pathology ; MicroRNAs/genetics ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Pilot Projects ; Pregnancy ; Transcriptome ; Young Adult
Chemische Substanzen	Biomarkers ; MicroRNAs
Sprache	Englisch
Erscheinungsdatum	2021-11-18
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2146365-7
ISSN	1533-0338 ; 1533-0346
ISSN (online)	1533-0338
ISSN	1533-0346
DOI	10.1177/15330338211067309
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 5871: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: The association between vitamin D receptor polymorphism and phases of chronic hepatitis B infection in HBV carriers in Thailand.

Ananchuensook, Prooksa / Suksawatamnauy, Sirinporn / Thaimai, Panarat / Sriphoosanaphan, Supachaya / Thanapirom, Kessarin / Teerapakpinyo, Chinachote / Pooworawan, Yong / Komolmit, Piyawat

PloS one

2022 Band 17, Heft 12, Seite(n) e0277907

Abstract: Vitamin D receptor (VDR) polymorphism partly regulates the immune system and is associated with hepatic flare in chronic Hepatitis B virus infection (HBV). Our study identified the association between two distinct phases, VDR polymorphisms and HBV ... ...

Abstract	Vitamin D receptor (VDR) polymorphism partly regulates the immune system and is associated with hepatic flare in chronic Hepatitis B virus infection (HBV). Our study identified the association between two distinct phases, VDR polymorphisms and HBV inactive carrier (IC) and chronic hepatitis (CH). Chronic HBV patients were enrolled from February to August 2020. An HBV viral load (VL) < 2,000 IU/ml twice for 6 months apart, with no prior history of HBV treatment, defined the IC phase. Six common polymorphisms in the VDR gene, including CdX-2, GATA, FokI, Bsml, ApaI, and TaqI, were studied using real-time PCR. The different outcomes in allele, genotype, and haplotype frequencies in between groups and linkage disequilibrium (LD) mapping were analyzed. Among 324 enrolled patients, there were 163 patients in IC and 161 patients in CH phases. The mean vitamin D levels were not statistically different between groups. The proportion of allele frequencies of CdX-2 in IC and CH was 53.7% and 62.7% for G allele, and 46.3% and 37.3% for A allele (p 0.019). The proportion of GG genotype of CdX-2 was less frequently found in patients with IC compared to that in patients with CH (27% vs 41%, p 0.028). By multivariate analysis, CdX-2 G/A genotypes were independently associated with IC, with adjusted odd ratio (OR) 1.83 (1.10-3.04), p 0.019. The LD mapping of single nucleotide polymorphisms (SNP) revealed high LD scores in Bsml/ApaI/TaqI (BAT) haplotype in both groups while, CdX-2/GATA and GATA/FokI demonstrated high LD score only in CH group. CdX-2 G/A genotypes were independently associated with IC status in Thai patients with chronic HBV infection. The difference in LD of the CdX-2/GATA and GATA/FokI haplotypes in between groups may represent a non-random selection resulting in the variation of immune control.
Mesh-Begriff(e)	Humans ; Alleles ; Case-Control Studies ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; Haplotypes ; Hepatitis B, Chronic/genetics ; Polymorphism, Single Nucleotide ; Receptors, Calcitriol/genetics
Chemische Substanzen	Receptors, Calcitriol
Sprache	Englisch
Erscheinungsdatum	2022-12-09
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0277907
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen